跳轉至內容
Merck
  • Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis.

Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis.

British journal of anaesthesia (2012-12-12)
N H Waldron, C A Jones, T J Gan, T K Allen, A S Habib
摘要

The analgesic efficacy and adverse effects of a single perioperative dose of dexamethasone are unclear. We performed a systematic review to evaluate the impact of a single i.v. dose of dexamethasone on postoperative pain and explore adverse events associated with this treatment. MEDLINE, EMBASE, CINAHL, and the Cochrane Register were searched for randomized, controlled studies that compared dexamethasone vs placebo or an antiemetic in adult patients undergoing general anaesthesia and reported pain outcomes. Forty-five studies involving 5796 patients receiving dexamethasone 1.25-20 mg were included. Patients receiving dexamethasone had lower pain scores at 2 h {mean difference (MD) -0.49 [95% confidence interval (CI): -0.83, -0.15]} and 24 h [MD -0.48 (95% CI: -0.62, -0.35)] after surgery. Dexamethasone-treated patients used less opioids at 2 h [MD -0.87 mg morphine equivalents (95% CI: -1.40 to -0.33)] and 24 h [MD -2.33 mg morphine equivalents (95% CI: -4.39, -0.26)], required less rescue analgesia for intolerable pain [relative risk 0.80 (95% CI: 0.69, 0.93)], had longer time to first dose of analgesic [MD 12.06 min (95% CI: 0.80, 23.32)], and shorter stays in the post-anaesthesia care unit [MD -5.32 min (95% CI: -10.49 to -0.15)]. There was no dose-response with regard to the opioid-sparing effect. There was no increase in infection or delayed wound healing with dexamethasone, but blood glucose levels were higher at 24 h [MD 0.39 mmol litre(-1) (95% CI: 0.04, 0.74)]. A single i.v. perioperative dose of dexamethasone had small but statistically significant analgesic benefits.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
地塞米松-水溶性, suitable for cell culture, BioReagent
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
地塞米松 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
地塞米松, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
地塞米松, meets USP testing specifications
Sigma-Aldrich
地塞米松, tested according to Ph. Eur.
Supelco
地塞米松, VETRANAL®, analytical standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard